Clinical validation of comprehensive time- and frequency-domain photoplethysmography features from a single-sensor system for non-invasive assessment of vascular load and systolic blood pressure
Authors:
Open Access
- 29 October 2025
- journal article
- physiology
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 16, 1695391
Abstract
Objective: Hypertension remains a silent yet powerful driver of cardiovascular disease—one of the world’s leading causes of death. Despite being treatable, it often goes undetected until complications arise. Photoplethysmography (PPG), a low-cost, non-invasive tool, holds promise for identifying vascular changes linked to high blood pressure. However, current single-site methods primarily focus on time-domain signals, often missing rich spectral data that could enhance early detection of hypertensive changes. Methods: We designed a compact, noise-resistant PPG acquisition system (Taiwan Patent No. 114206342) aimed at real-world usability and recruited 590 adults from cardiology outpatient clinics. Using a validated oscillometric device, systolic blood pressure (SBP) was measured and categorized into four groups (≤120, 121–139, 140–159, ≥160 mmHg). Ninety-second fingertip PPG recordings (500 Hz) underwent careful pre-processing—filtering, normalization, and artifact rejection. We extracted 19 features covering waveform shape, sharpness, heart rate variability (HRV), and frequency-domain harmonic ratios. Group differences were assessed using ANOVA or Kruskal–Wallis tests, with post hoc analyses and effect size reporting (epsilon squared, ε 2 ). Results: Several features demonstrated strong associations with SBP levels. Waveform sharpness indices (1_10, 1_8, 1_6, 1_5, 1_3, 1_2) and harmonic ratios (H2/H1, H3/H1, H4/H1) showed a progressive decline as SBP increased—signaling a loss of higher-frequency components likely due to vascular stiffening. Time-domain features revealed that individuals with elevated SBP had prolonged systolic phases, shorter diastolic intervals, and higher Ts/Td ratios. Peak amplitudes (P1, P2), systolic and diastolic slopes, and overall waveform area also differed significantly by group. Effect sizes ranged from small to moderate, with the most pronounced changes seen in waveform sharpness. Conclusion: Our results demonstrate the promise of a single-sensor PPG-based approach for monitoring hypertension-related, subtle vascular alterations by combining morphological and spectral information. Progressive decline in harmonic ratios provides new information on arterial stiffening and changed wave reflections. This level of physiological depth combined with a remarkably simple and portable approach is the key that could allow wearable devices to provide immediate blood pressure screening for unprecedented widespread user engagement.Keywords
This publication has 48 references indexed in Scilit:
- SPRINT Treatment Among Adults With Chronic Kidney Disease From 2 Large Health Care SystemsJAMA Network Open, 2025
- Blood pressure estimation and classification using a reference signal-less photoplethysmography signal: a deep learning frameworkPhysical and Engineering Sciences in Medicine, 2023
- Structural and functional state of various parts of skin microcirculation at an early stage of hypertension in working-age menMicrovascular Research, 2022
- A multistage deep neural network model for blood pressure estimation using photoplethysmogram signalsComputers in Biology and Medicine, 2020
- Predictive value of the augmentation index derived vascular age in patients with newly diagnosed atherosclerosisHeart and Vessels, 2016
- Characteristics of beat-to-beat photoplethysmography waveform indexes in subjects with metabolic syndromeMicrovascular Research, 2016
- Baseline predictors of central aortic blood pressure: A PEAR substudyJournal of the American Society of Hypertension, 2014
- Time domain analysis of the arterial pulse in clinical medicineMedical & Biological Engineering & Computing, 2008
- Global burden of blood-pressure-related disease, 2001The Lancet, 2008
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 2002